US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 3.2600
- +0.1300+4.15%
Close Nov 18 16:00 ET
12.44MMarket Cap-483P/E (TTM)
3.4300High3.1200Low15.74KVolume3.2300Open3.1300Pre Close50.21KTurnover0.47%Turnover RatioLossP/E (Static)3.82MShares29.080052wk High-1.34P/B10.86MFloat Cap3.000052wk Low--Dividend TTM3.33MShs Float294.0000Historical High--Div YieldTTM9.90%Amplitude3.0000Historical Low3.1900Avg Price1Lot Size
About NLS Pharmaceutics Company
NLS Pharmaceutics AG engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders. These disorders include narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as ADHD. The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.
Company Profile
SymbolNLSP
Company NameNLS Pharmaceutics
Listing DateJan 29, 2021
Issue Price4.15
Founded2015
CEOMr. Alexander Zwyer
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
AddressAlter Postplatz 2
CityStans
ProvinceNidwalden
CountrySwitzerland
Zip Code6370
Phone41-41-618-80-00
Websitehttp://nlspharma.com
Company Executives
-
Name
- Position
- Salary
-
Alexander Zwyer
- Chief Executive Officer and Director
- --
-
Dr. Eric Konofal, M.D.
- Chief Scientific Officer
- --
-
Elena Thyen-Pighin
- Chief Financial Officer and Head of Finance and Human Resources
- --
-
George Apostol
- Chief Medical Officer and Global Head of Research and Development
- --
-
Ronald Hafner
- Chairman of the Board
- --
-
Florence Allouche Aknin
- Independent Director
- --
-
Gian-Marco Rinaldi
- Independent Director
- --
-
Audrey Greenberg
- Independent Director
- --
-
Claudio L. A. Bassetti
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data